Skip to main content
Log in

Bosentan

A Review of its Use in the Management of Mildly Symptomatic Pulmonary Arterial Hypertension

  • Adis Drug Evaluation
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Summary

Abstract

Bosentan (Tracleer®) is an orally administered dual endothelin-1 (ET-1) receptor antagonist approved for use in patients with WHO class II (mildly symptomatic) pulmonary arterial hypertension (PAH).

Oral bosentan therapy was beneficial and generally well tolerated in patients with mildly symptomatic PAH. In a well designed, placebo-controlled trial in adolescents and adults with mildly symptomatic PAH, pulmonary vascular resistance was significantly reduced with bosentan relative to placebo, but the 6-minute walk distance did not increase significantly. Similarly, pediatric patients (most of whom had mildly symptomatic PAH) in a small uncontrolled trial experienced some improvement in hemodynamic variables with bosentan, but did not experience a significant increase in exercise capacity. Adverse events associated with bosentan were consistent with those seen in other indications, with major concerns being the potential for teratogenicity and hepatotoxicity, for which regular liver function monitoring is recommended. Overall, considering the progressive nature of PAH, bosentan extends the treatment options available to patients with mildly symptomatic PAH.

Pharmacological Properties

Bosentan is a dual ET-1 receptor antagonist that binds competitively and specifically to endothelin A and B receptors, thereby antagonizing the binding of ET-1. Treatment with bosentan improved hemodynamic variables in patients with PAH.

The pharmacokinetics of bosentan are dose- and time-dependent; clearance and volume of distribution decrease with increasing intravenous doses and increase with time. In healthy adults, steady state was reached after 3–5 days. The peak plasma concentration of bosentan at steady-state, and its steady-state area under the plasma concentration-time curve from 0 to 24 hours was ≈4022–60% lower with multiple dose than with single-dose administration, which may be because of dose-dependent auto-induction of metabolizing liver enzymes that peaks after ≈4–5 days of administration.

Bosentan is metabolized by cytochrome P450 (CYP) 2C9 and CYP3A4 into three metabolites, Ro 48-5033 (major metabolite), Ro 47-8634, and Ro 64–1056. Only Ro 48–5033 is metabolically active, accounting for up to 20% of drug activity. Oral bosentan is eliminated largely via feces in healthy adults, mainly as Ro 48–5033; less than 3% of a dose is excreted in urine. Bosentan has a half-life of 5–7 hours after multiple-dose administration.

Compared with healthy adults, patients with PAH may have greater exposure (≈2-fold increase) to bosentan and its active metabolite. The pharmacokinetics of bosentan in pediatric patients with PAH were generally similar to those in healthy adults. However, compared with patients with PAH, steady-state exposure in pediatric patients was 31–61% lower, the reason for which is unclear, but may be attributed to increased metabolism and excretion.

As bosentan is both a substrate and an inducer of hepatic CYP2C9 and CYPA34 isoenzymes, it may interact with other drugs that are also substrates, inducers, or inhibitors of these enzymes. Therefore, concomitant use of bosentan with glibenclamide (glyburide), fluconazole, rifampicin (rifampin) [in the EU], and both a CYP3A4 inhibitor and a CYP2C9 inhibitor is not recommended. Bosentan is contraindicated in pregnant women and in child-bearing women who are not using reliable methods of contraception because of an associated risk of teratogenicity and contraception failure.

Therapeutic Efficacy

Oral bosentan therapy was beneficial in adolescents and adults with mildly symptomatic PAH. In the randomized, double-blind, multicenter, placebo-controlled EARLY trial (n = 185), bosentan 125 mg twice daily for 6 months significantly reduced pulmonary vascular resistance, but there was no significant increase in exercise capacity as assessed by the 6-minute walk distance (co-primary endpoints). Bosentan therapy also significantly improved several other hemodynamic variables and delayed clinical worsening of disease in these patients (secondary endpoints). In addition, in a small, open-label, uncontrolled trial in pediatric patients, most of whom were mildly symptomatic, there was significant improvement from baseline in several hemodynamic variables with bosentan 31.25–125 mg twice daily for 3 months, but there was no significant increase in exercise capacity.

Tolerability

Bosentan was generally well tolerated in adolescents and adults with mildly symptomatic PAH and in pediatric patients with PAH. Abnormal liver function tests were the most common (≥5%) treatment-emergent adverse event that occurred at least twice as frequently with bosentan compared with placebo in adolescents and adults with mildly symptomatic PAH during 6 months’ therapy in the EARLY trial (8% vs 3%).

As with other ET-1 receptor antagonists, bosentan therapy is associated with transient increases in the levels of liver aminotransferases. However, these returned to pre-treatment levels either spontaneously or after dose reduction or discontinuation in clinical trials. Elevations in aminotransferase levels of >3 times the upper limit of normal were reported in 13% of bosentan versus 2% of placebo recipients in adolescents and adults with mildly symptomatic PAH during 6 months’ therapy in the EARLY trial. Postmarketing data suggest that the incidence and severity of elevated aminotransferase levels in clinical practice were generally similar to those seen in clinical trials. Treatment with bosentan may also be associated with a decreased hemoglobin levels; in the EARLY trial, 5% of bosentan recipients with mildly symptomatic PAH showed a decrease from baseline in hemoglobin levels during 6 months’ therapy, resulting in values of <10g/dL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Fig. 1
Table VII

Similar content being viewed by others

References

  1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. Epub 2009 Aug 27.

  2. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 Jun 30; 54 (1 Suppl.): S55–66.

    Article  PubMed  Google Scholar 

  3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004 Sep 30; 351(14): 1425–36.

    Article  PubMed  CAS  Google Scholar 

  4. Highland KB. Pulmonary arterial hypertension. Am J Med Sci 2008 Jan; 335(1): 40–5.

    Article  PubMed  Google Scholar 

  5. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991 Sep 1; 115(5): 343–9.

    PubMed  Google Scholar 

  6. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J 2007 Dec; 30(6): 1103–10.

    Article  PubMed  CAS  Google Scholar 

  7. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006 May 1; 173(9): 1023–30.

    Article  PubMed  Google Scholar 

  8. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007 Jul; 30(1): 104–9.

    Article  PubMed  CAS  Google Scholar 

  9. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004 Oct 14; 351(16): 1655–65.

    Article  PubMed  CAS  Google Scholar 

  10. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987 Aug; 107(2): 216–23.

    PubMed  CAS  Google Scholar 

  11. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve Clin J Med 2003; 70 Suppl. 1: S2–8.

    Article  PubMed  Google Scholar 

  12. Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 2008; 68(8): 1049–66.

    Article  PubMed  CAS  Google Scholar 

  13. Kahler CM, Colleselli D. Pulmonary arterial hypertension (PAH) in connective tissue diseases. Rheumatology (Oxford) 2006 Oct; 45 Suppl. 3: iii11–3.

    Article  Google Scholar 

  14. Proudman SM, Stevens WM, Sahhar J, et al. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007; 37(7): 485–94.

    Article  PubMed  CAS  Google Scholar 

  15. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 Jun 30; 54 (1 Suppl.): S43–54.

    Article  PubMed  Google Scholar 

  16. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases: from diagnosis to treatment. Rheumatology (Oxford) 2006; 45 Suppl. 4: iv22–5.

    Article  Google Scholar 

  17. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997 Jan 9; 336(2): 111–7.

    Article  PubMed  CAS  Google Scholar 

  18. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009 Jun 30; 54 (1 Suppl.): S20–31.

    Article  PubMed  CAS  Google Scholar 

  19. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009 Jun 30; 54 (1 Suppl.): S10–9.

    Article  PubMed  CAS  Google Scholar 

  20. Traiger GL. Pulmonary arterial hypertension. Crit Care Nurs Q 2007 Jan 31; 30(1): 20–43.

    PubMed  Google Scholar 

  21. Murali S. Pulmonary arterial hypertension. Curr Opin Crit Care 2006 Jun; 12(3): 228–34.

    Article  PubMed  Google Scholar 

  22. Braun-Moscovici Y, Nahir AM, Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum 2004; 34(1): 442–53.

    Article  PubMed  CAS  Google Scholar 

  23. European Medicines Agency. Tracleer (bosentan) 62.5 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/tracleer/H-401-PI-en.pdf [Accessed 2009 Aug 6].

  24. Actelion Pharmaceuticals US Inc. Tracleer (bosentan) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021290s012lbl.pdf [Accessed 2009 Aug 19].

  25. Oldfield V, Lyseng-Williamson KA. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. Am J Cardiovasc Drugs 2006; 6(3): 189–208.

    Article  PubMed  CAS  Google Scholar 

  26. Prakash A, Perry CM. Bosentan. Am J Cardiovasc Drugs 2002; 2(5): 335–43; discussion 343.

    Article  PubMed  CAS  Google Scholar 

  27. Dingemanse J, van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43(15): 1089–115.

    Article  PubMed  CAS  Google Scholar 

  28. Barst RJ. A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag 2007; 3(1): 11–22.

    PubMed  CAS  Google Scholar 

  29. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994 Jul; 270(1): 228–35.

    PubMed  CAS  Google Scholar 

  30. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008 Feb; 31(2): 407–15.

    Article  PubMed  CAS  Google Scholar 

  31. Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs 2008; 8(3): 171–85.

    Article  PubMed  CAS  Google Scholar 

  32. Opitz CF, Ewert R, Kirch W, et al. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008 Jun 17; 29: 1936–48.

    Article  PubMed  CAS  Google Scholar 

  33. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993 Jun 17; 328(24): 1732–9.

    Article  PubMed  CAS  Google Scholar 

  34. Dupuis J, Cernacek P, Tardif JC, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 1998 Apr; 135(4): 614–20.

    Article  PubMed  CAS  Google Scholar 

  35. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996 Oct; 81(4): 1510–5.

    PubMed  CAS  Google Scholar 

  36. Hiramoto Y, Shioyama W, Kuroda T, et al. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ J 2007 Mar; 71(3): 367–9.

    Article  PubMed  CAS  Google Scholar 

  37. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003 Apr; 73(4): 372–82.

    Article  PubMed  CAS  Google Scholar 

  38. Galie N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008 Jun 21; 371(9630): 2093–100.

    Article  PubMed  CAS  Google Scholar 

  39. Sfikakis PP, Papamichael C, Stamatelopoulos KS, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007 Jun; 56(6): 1985–93.

    Article  PubMed  CAS  Google Scholar 

  40. Sauvageau S, Thorin E, Villeneuve L, et al. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels. Pulm Pharmacol Ther 2009 Aug; 22(4): 311–7.

    Article  PubMed  CAS  Google Scholar 

  41. Mouchaers KT, Schalij I, Versteilen AM, et al. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2009 Jul; 297(1): H200–7.

    Article  PubMed  CAS  Google Scholar 

  42. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27(12): 1485–94.

    Article  PubMed  CAS  Google Scholar 

  43. European Medicines Agency. Tracleer: updated scientific discussion (tracleer-H-401-II-37-AR) [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/tracleer/tracleerM2.htm [Accessed 2009 Aug 6].

  44. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheumatol 2009 Apr; 36(4): 760–7.

    Article  PubMed  CAS  Google Scholar 

  45. Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008 Aug; 67(8): 1121–6.

    Article  PubMed  CAS  Google Scholar 

  46. Hamaguchi Y, Fujimoto M, Hasegawa M, et al. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension [letter]. J Dermatol Sci 2009 Mar 31; 55(1): 66–7.

    Article  PubMed  CAS  Google Scholar 

  47. Giannelli G, Iannone F, Marinosci F, et al. Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. Eur J Clin Invest 2006 Sep; 36 Suppl. 3: 73–7.

    Article  PubMed  CAS  Google Scholar 

  48. Giannelli G, Iannone F, Marinosci F, et al. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 2005 Mar; 21(3): 327–32.

    Article  PubMed  CAS  Google Scholar 

  49. Yuyama H, Noguchi Y, Fujimori A, et al. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol 2004 Sep 13; 498(1–3): 171–7.

    Article  PubMed  CAS  Google Scholar 

  50. Wu-Wong JR, Dixon DB, Chiou WJ, et al. Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics. J Pharmacol Exp Ther 1997 May; 281(2): 791–8.

    PubMed  CAS  Google Scholar 

  51. Yang Z, Krasnici N, Lüscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999 Jul 6; 100(1): 5–8.

    Article  PubMed  CAS  Google Scholar 

  52. Kunichika N, Landsberg JW, Yu Y, et al. Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med 2004 Nov 15; 170(10): 1101–7.

    Article  PubMed  Google Scholar 

  53. European Medicines Agency. Tracleer (bosentan) scientific discusssion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/tracleer/100002en6.pdf [Accessed 2009 Aug 6].

  54. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 1999 Jul; 27(7): 810–5.

    PubMed  CAS  Google Scholar 

  55. Dingemanse J, Schaarschmidt D, van Giersbergen PLM. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet 2003; 42(3): 293–301.

    Article  PubMed  CAS  Google Scholar 

  56. Dingemanse J, Bodin F, Weidekamm E, et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2002 Mar; 42: 283–9.

    Article  PubMed  CAS  Google Scholar 

  57. Weber C, Schmitt R, Birnboeck H, et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 1999; 39: 703–14.

    Article  PubMed  CAS  Google Scholar 

  58. Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996 Aug; 60(2): 124–37.

    Article  PubMed  CAS  Google Scholar 

  59. van Giersbergen PL, Popescu G, Bodin F, et al. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2003 Jan; 43(1): 15–22.

    Article  PubMed  Google Scholar 

  60. Dingemanse J, van Giersbergen PLM. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int J Clin Pharmacol Ther 2002 Jul; 40(7): 310–6.

    PubMed  CAS  Google Scholar 

  61. Binet I, Wallnöfer A, Weber C, et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int 2000 Jan; 57(1): 224–31.

    Article  PubMed  CAS  Google Scholar 

  62. van Giersbergen PLM, Treiber A, Clozel M, et al. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 2002; 71: 253–62.

    Article  PubMed  Google Scholar 

  63. van Giersbergen PLM, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002; 53: 589–95.

    Article  PubMed  Google Scholar 

  64. Weber C, Banken L, Birnboeck H, et al. Effect of endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999 Aug; 39(8): 847–54.

    Article  PubMed  CAS  Google Scholar 

  65. Weber C, Banken L, Birnboeck H, et al. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol 1999 Jun; 47:701–6.

    Article  PubMed  CAS  Google Scholar 

  66. Paul GA, Gibbs JS, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60(1): 107–12.

    Article  PubMed  CAS  Google Scholar 

  67. van Giersbergen PLM, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006 Mar; 44(3): 113–8.

    PubMed  Google Scholar 

  68. Treiber A, Schneiter R, Häusler S, et al. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007 Aug; 35(8): 1400–7.

    Article  PubMed  CAS  Google Scholar 

  69. van Giersbergen PL, Treiber A, Schneiter R, et al. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 2007 Mar; 81(3): 414–9.

    Article  PubMed  Google Scholar 

  70. Burgess G, Hoogkamer H, Collings L, et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008 Jan; 64(1): 43–50.

    Article  PubMed  CAS  Google Scholar 

  71. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007 Aug; 30(2): 338–44.

    Article  PubMed  CAS  Google Scholar 

  72. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2–11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 2008 Aug; 64(2): 200–4.

    Article  PubMed  CAS  Google Scholar 

  73. Taichman DB. Therapy for pulmonary arterial hypertension: the more, the merrier? Ann Intern Med 2008 Oct 21; 149(8): 583–5.

    PubMed  Google Scholar 

  74. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association [published erratum appears in Circulation 2009 Jul 14; 120 (2): e13]. Circulation 2009 Apr 28; 119(16): 2250–94.

    Article  PubMed  Google Scholar 

  75. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005 Sep; 258(3): 199–215.

    Article  PubMed  CAS  Google Scholar 

  76. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009 Jun 30; 54 (1 Suppl.): S78–84.

    Article  PubMed  CAS  Google Scholar 

  77. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009 Feb; 30(4): 394–403.

    Article  PubMed  Google Scholar 

  78. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006. Heart 2009 Feb; 95(4): 312–7.

    Article  PubMed  CAS  Google Scholar 

  79. Juergens UR, Racke K, Uen S, et al. Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism. Pulm Pharmacol Ther 2008; 21(3): 533–9.

    Article  PubMed  CAS  Google Scholar 

  80. McLaughlin VV, Shillington A, Rich S, et al. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106(12): 1477–82.

    Article  PubMed  CAS  Google Scholar 

  81. Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 2009 Apr; 7(2): 225–33.

    Article  PubMed  CAS  Google Scholar 

  82. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 Jun 10; 117(23): 3010–9.

    Article  PubMed  CAS  Google Scholar 

  83. Simonneau G, Barst RJ, Galie N, et al. on behalf of the Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002 Mar 15; 165(6): 800–4.

    PubMed  Google Scholar 

  84. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension [published erratum appears in N Engl J Med 2006 Jun 1; 354 (22): 2400–1]. N Engl J Med 2005 Nov 17; 353(20): 2148–57.

    Article  PubMed  CAS  Google Scholar 

  85. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009 Jun 9; 119(22): 2894–903.

    Article  PubMed  CAS  Google Scholar 

  86. Steiner MK, Preston IR. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2008; 4(5): 943–52.

    PubMed  CAS  Google Scholar 

  87. Gilead Sciences Inc. Letairis (ambrisentan) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022081s010lbl.pdf [Accessed 2009 Aug 19].

  88. European Medicines Agency. Volibris (ambrisentan) 5 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/volibris/volibris.htm [Accessed 2009 Aug 6].

  89. Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism. Respir Med 2009 Jul; 103(7): 951–62.

    Article  PubMed  Google Scholar 

  90. European Medicines Agency. Revatio (sildenafil) tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Revatio/emea-combined-h638en.pdf [Accessed 2009 Aug 19].

  91. Pfizer Labs. Revatio (slidenafil) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021845s006lbl.pdf [Accessed 2009 Sep 8].

  92. Eli Lilly and Company. Adcirca (tadalafil) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf [Accessed 2009 Sep 8].

  93. Baxter Pharmaceutical Solutions LLC. Remodulin (treprostinil sodium) injection: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021272s008lbl.pdf [Accessed 2009 Aug 19].

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sohita Dhillon.

Additional information

Various sections of the manuscript reviewed by: S.A. Antoniu, Department of Internal Medicine-Pulmonary Disease, University of Medicine and Pharmacy “Gr.T.Popa” Iasi, Iasi, Romania; E. Hachulla, Department of Internal Medicine, National Scleroderma Center, Hôpital Claude-Huriez, Lille, France; U.R. Juergens, Department of Pneumology, Allergology, Sleep Medicine, Bonn University Hospital, Medical Clinic and Outpatient Clinic II, Bonn, Germany; I.M. Lang, Department of Internal Medicine II — Cardiology, Allgemeines Krankenhaus Wien, Medical University of Vienna, Vienna, Austria; M. Matucci-Cerinic, Division of Rheumatology AOUC, Department of BioMedicine, University of Florence, Florence, Italy; K.K. Talwar, Department of Cardiology, Postgraduate Institute of Medical Education & Research, Chandigarh, India; U. Thadani, Department of Medicine, Cardiology Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘bosentan’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘bosentan’ and (‘pulmonary arterial hypertension’ or ‘pulmonary hypertension’ or ‘PAH’). Searches were last updated 8 September 2009.

Selection: Studies in patients with mild pulmonary arterial hypertension who received bosentan. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Bosentan, endothelin receptor antagonists, mild pulmonary arterial hypertension, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhillon, S., Keating, G.M. Bosentan. Am J Cardiovasc Drugs 9, 331–350 (2009). https://doi.org/10.2165/11202270-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11202270-000000000-00000

Keywords

Navigation